Keywords: Nonlocal continuum mechanics; Non-ordinary state based peridynamics; Fracture in rock; Semi-circular bend specimen; Mode-I; Mode-II; Mixed mode; Fracture toughness; MTS; GMTS;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AE; adverse event; ClfA; clumping factor A; cLIA; four-plex competitive Luminex® immunoassay; CI; confidence interval; CP; capsular polysaccharide; CRM197; diphtheria toxin; DMC; data monitoring committee; FBI; fibrinogen-binding inhibition; FDA; Food an
Keywords: IIV-HD; high-dose inactivated influenza vaccine; HA; hemagglutinin; IIV-SD; standard-dose inactivated intramuscular influenza vaccine; CI; confidence interval; HAI; hemagglutination inhibition; PD-ILI; protocol-defined influenza-like illness; NP; nasophar
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III
Keywords: Pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV); 1-dose vial presentation; 4-dose vial presentation; Immunologic non-inferiority; Safety; Infants; AE; adverse event; ATP; according-to-protocol; CI; confidence interva
Antibody persistence and booster response 68â¯months after vaccination at 2-10â¯years of age with one dose of MenACWY-TT conjugate vaccine
Keywords: AEs; adverse events; ATP; according-to-protocol; CIs; confidence intervals; GI; gastrointestinal; GMTs; geometric mean titers; hSBA; serum bactericidal activity assay using human complement; IMD; invasive meningococcal disease; M; month; MenB; meningococc
Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults
Keywords: PPSV23; 23-valent pneumococcal polysaccharide vaccine; IPD; invasive pneumococcal diseases; PCV13; 13-valent pneumococcal conjugate vaccine; OPA; opsonophagocytic assay; MOPA; multiplexed OPA; OBB; opsonization buffer B; BRC; Baby rabbit complement; THY;
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials
Keywords: HPV; human papillomavirus; VLP; virus-like particle; 9vHPV; 9-valent human papillomavirus; cLIA; competitive Luminex immunoassay; GMTs; geometric mean titers; CI; confidence interval; mMU/mL; milli-Merck units per milliliter; qHPV; quadrivalent human papi
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men
Keywords: 9vHPV vaccine; 9-valent HPV vaccine; AE; adverse event; ANOVA; analysis of variance; CI; confidence interval; cLIA; competitive Luminex immunoassay; EU; European Union; GMTs; geometric mean titres; HPV; human papilloma virus; qHPV vaccine; quadrivalent HP
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults
Keywords: AEs; adverse events; ATP; according-to-protocol; CIs; confidence intervals; CMI; cell-mediated immune; COPD; chronic obstructive pulmonary disease; EU; ELISA units; GMCs; geometric mean concentrations; GMTs; geometric mean titers; ICS; intracellular cytok
(â)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin
Keywords: Diphenylpyridazinone derivatives; NSC 613241; (â)-Rhazinilam; Tubulin polymer of aberrant morphology; Inhibition of tubulin assembly; Glutaraldehyde-fixed microtubules; DPP; diphenylpyridazinone; HPLC; high-performance liquid chromatography; MAPs; micro
Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years
Keywords: AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CIs; confidence intervals; GMTs; geometric mean titers; HA; hemagglutinin antigen; HI; hemagglutination-inhibition; MAEs; med